Indian pharmaceutical company Divi’s Laboratories Ltd. plans to fight new tax adjustments related to the company’s transfer pricing and corporate tax positions.

Stay up-to-date with the Divis Labs Stock Liveblog, your trusted source for real-time updates and thorough analysis of a ...

Divi's Laboratories Limited has received a draft assessment order from the Income Tax Authority proposing ...

Discover the Divis Labs Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a ...

Divi's Laboratories faces a ₹570 crore draft tax assessment for FY23, citing Transfer Pricing and corporate tax adjustments.

Divi’s Labs could emerge as a key beneficiary of the global GLP-1 drug boom, with new peptide manufacturing contracts and ...

Divi’s Laboratories has received a draft tax assessment order proposing ₹570.51 crore in additions to FY23 income due to ...

India, March 12 -- Broking Jefferies is still optimistic about Divi's Laboratories and has stated that the company is set to ...

Mumbai: Divi's Laboratories Ltd has received a draft assessment order from the Income Tax Department proposing additions and ...

Earnings call Divi's Laboratories reported Q3 FY26 revenue of ₹2,692 Cr, up 12.1% YoY, with profit before tax (ex-exceptional) rising 17.6% YoY to ₹854 Cr. Gross margin improved significantly due to ...

HYDERABAD, India--(BUSINESS WIRE)--Juniper Networks (NYSE: JNPR), a leader in secure, AI-driven networks, today announced that Divi’s Laboratories (NSE: DIVISLAB), one of the largest active ...